Utah Medical Products Inc UTMD Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$72.23 up $1.19, 1.68% at close Nov 6
Last close · Previous close $71.04
- Market cap
- $229.98MAt the Nov 6 close
- P/E ratio
- 22.02On last 12 months’ EPS
- Diluted EPS
- $3.28Last 12 months
- Dividend yield
- 1.72%Last 12 months
Price chart
$72.23up $1.19, 1.68%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$71.04Nov 5
- Volume36.22KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume39.34KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $53.66 to $76.89; now $72.23
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
UTMD beat the S&P 500 in 4 of 7 periods.
| Period | UTMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | UTMD: down 2.2% S&P 500: down 5.6% | UTMD beat the S&P 500 by 3.4 percentage points Beat |
| 3M | UTMD: up 3.7% S&P 500: down 4.1% | UTMD beat the S&P 500 by 7.8 percentage points Beat |
| YTD | UTMD: up 30.9% S&P 500: up 8.7% | UTMD beat the S&P 500 by 22.2 percentage points Beat |
| 1Y | UTMD: up 27.2% S&P 500: up 10.9% | UTMD beat the S&P 500 by 16.3 percentage points Beat |
| Long term | ||
| 3Y | UTMD: down 4.5% S&P 500: up 75.0% −1.5% vs +20.5% a year | UTMD trailed the S&P 500 by 79.5 percentage points Trailed |
| 5Y | UTMD: down 23.5% S&P 500: up 67.8% −5.2% vs +10.9% a year | UTMD trailed the S&P 500 by 91.3 percentage points Trailed |
| 10Y | UTMD: up 46.2% S&P 500: up 313.1% +3.9% vs +15.2% a year | UTMD trailed the S&P 500 by 266.9 percentage points Trailed |
$10,000 invested in UTMD 10 years ago (Nov 4, 2016) would be worth about $14,622 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
UTMD beat the S&P 500 in 4 of 7 periods.
| Period | UTMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | UTMD: down 2.2% S&P 500: down 5.6% | UTMD beat the S&P 500 by 3.4 percentage points Beat |
| 3M | UTMD: up 3.2% S&P 500: down 4.3% | UTMD beat the S&P 500 by 7.5 percentage points Beat |
| YTD | UTMD: up 29.1% S&P 500: up 7.8% | UTMD beat the S&P 500 by 21.3 percentage points Beat |
| 1Y | UTMD: up 24.8% S&P 500: up 9.7% | UTMD beat the S&P 500 by 15.1 percentage points Beat |
| Long term | ||
| 3Y | UTMD: down 9.7% S&P 500: up 68.8% −3.4% vs +19.1% a year | UTMD trailed the S&P 500 by 78.5 percentage points Trailed |
| 5Y | UTMD: down 30.6% S&P 500: up 56.9% −7.1% vs +9.4% a year | UTMD trailed the S&P 500 by 87.5 percentage points Trailed |
| 10Y | UTMD: up 24.3% S&P 500: up 252.6% +2.2% vs +13.4% a year | UTMD trailed the S&P 500 by 228.3 percentage points Trailed |
$10,000 invested in UTMD 10 years ago (Nov 4, 2016) would be worth about $12,432 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$124.71
Closing high on . Now 42.1% below that record.
Split-adjusted daily closes since Mar 8, 1999.
Stock splits
UTMD hasn’t split since its price history begins in 1999.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
22.0×The Nov 6 close ÷ diluted EPS over the last 12 months ($3.28)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
UTMD trades at 22.0× its earnings over the last 12 months, above its 5-year median of 18.5×. In plain terms, buyers are paying about $22 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 6.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.9×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 9.3×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 4.98%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $142.65MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own UTMD DCF in Excel. Value Utah Medical Products with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $36.11Mdown 7.0%
- Net income
- $10.49Mdown 16.5%
- Diluted EPS
- $3.28down 12.3%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $10.01M | $3.56M | $1.02 |
| Q4 FY24 (Dec 31, 2024) | $9.16M | $2.90M | $0.86 |
| Q1 FY25 (Mar 31, 2025) | $9.71M | $3.04M | $0.92 |
| Q2 FY25 (Jun 30, 2025) | $9.95M | $3.05M | $0.94 |
| Q3 FY25 (Sep 30, 2025) | $9.81M | $2.63M | $0.82 |
| Q4 FY25 (Dec 31, 2025) | $9.05M | $2.57M | $0.80 |
| Q1 FY26 (Mar 31, 2026) | $8.72M | $2.60M | $0.82 |
| Q2 FY26 (Jun 30, 2026) | $8.53M | $2.69M | $0.84 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $49.05M | $14.79M | $4.04 |
| FY22 (Dec 31, 2022) | $52.28M | $16.47M | $4.52 |
| FY23 (Dec 31, 2023) | $50.22M | $16.64M | $4.57 |
| FY24 (Dec 31, 2024) | $40.90M | $13.87M | $3.96 |
| FY25 (Dec 31, 2025) | $38.52M | $11.29M | $3.48 |
Margins
- Gross 57.9%
- Operating 28.4%
- Net 29.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $11.45MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$11.85MLast 12 months
- Capital spending$400.00KLast 12 months
- 31.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.85MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$3.94MLast 12 months
- Total returned$5.79MLast 12 months
51% of free cash flow
Balance sheet
- $87.53MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$195.00KAs of Jun 30, 2026
- Net cash$87.33MAs of Jun 30, 2026
- 48.62As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 8 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 8.7%Last 12 months
Over the last 12 months, Utah Medical Products’s net income was 8.7% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 8.5%Last 12 months
Over the last 12 months, Utah Medical Products’s net income was 8.5% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $1.05 |
| 2017 | $1.07 |
| 2018 | $1.09 |
| 2019 | $1.11 |
| 2020 | $1.13 |
| 2021 | $2.86 |
| 2022 | $1.17 |
| 2023 | $1.19 |
| 2024 | $1.21 |
| 2025 | $1.23 |
| 2026 (to date) | $0.93 |
Dividend details
- $1.24Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 1.72%; 5-yr low 0.91%, 5-yr high 3.55%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 1.85%.
- $0.31Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- FrequencyQuarterly4 payments in the last 12 months
- up 1.7% a yearFull years 2020–2025
The compound annual growth rate of the full-year dividend per share from 2020 to 2025.
- 3 yearsThrough 2025
How many calendar years in a row the full-year amount has risen, through 2025.
- 37.8%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Utah Medical Products Inc
Utah Medical Products, Inc. (UTMD) is in the business of producing medical devices that are, disposable and for hospital use. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as products sold to outpatient clinics and physician's offices. It's products are sold directly to end users in the United States domestic market by Its own direct sales representatives and independent manufacturers' representatives. In addition, some of its products are sold through specialty distributors, national hospital distribution companies and other medical device manufacturers. Internationally, products are sold directly to end users in the United Kingdom and Australia, and through other medical device companies and through independent medical products distributors. On March 18, 2011, UTMD acquierd Femcare Holdings Ltd. (Femcare).
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Utah, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
UTMD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
UTMD stock FAQ
What is UTMD stock’s price today?
Utah Medical Products (UTMD) traded at $72.23 at the close on , up $1.19 (1.68%) from the previous close of $71.04. Over the past 52 weeks it has traded between $53.66 and $76.89.
If you invested $1,000 in UTMD 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in UTMD on would be worth about $1,462 at the close on , a total return of +46.2%. The same $1,000 would be worth $765 if invested five years ago, $1,272 if invested one year ago, and $3,316 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market capitalization is about $230.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $72.23 (how market cap works). Utah Medical Products reported 3.18M shares outstanding at the end of its latest quarter ().
What is UTMD’s P/E ratio?
UTMD trades at 22.0 times its diluted earnings over the four quarters to ($3.28 per share), at the close. Over the past five years its P/E has ranged from 13.1 to 32.3, with a median of 18.5. (How the P/E ratio works.)
How much revenue does Utah Medical Products make?
Utah Medical Products reported $36.1 million of revenue over the four quarters to , down 7.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $8.5 million, down 14.3% from a year earlier.
Is Utah Medical Products profitable?
Yes. Utah Medical Products earned $10.5 million of net income over the four quarters to , a net margin of 29.0%, and its operating margin was 28.4% (what margins tell you).
What are UTMD’s earnings per share?
UTMD’s diluted earnings per share were $3.28 over the four quarters to , compared with $3.74 in the twelve months before. The latest quarter (Q2 FY26) brought $0.84 per share, against $0.94 a year earlier (how EPS works).
Does UTMD pay a dividend?
Yes. Utah Medical Products pays a quarterly dividend. The most recent was $0.31 per share, with an ex-dividend date of . Over the last twelve months it paid $1.24 per share, a 1.72% yield at the close, and the full-year dividend has risen 3 years in a row (how dividend yield works).
Based on the last 12 months’ payments ($1.24 per share), and if the next 12 months match the last 12, 100 shares would receive about $124 over 12 months, and $1,000 over 12 months would take about 807 shares, roughly $58,290 at the close. Dividends can change.
What is UTMD’s 52-week high and low?
Over the past 52 weeks UTMD has traded as low as $53.66 and as high as $76.89. At $72.23 at the close on , it is 6.1% below that high and 34.6% above the low.
What is UTMD’s all-time high?
UTMD’s highest closing price was $124.71 on , adjusted for stock splits. At $72.23 at the close on , it is 42.1% below that record.
Has UTMD stock ever split?
No. UTMD hasn’t split since its price history begins in 1999.
How has UTMD stock performed?
Including dividends and measured to the close on , UTMD has returned +30.9% so far this year and +27.2% over the past year, and −23.5% over five years (−5.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Utah Medical Products in?
Utah Medical Products is in the Healthcare sector and the Medical Instruments & Supplies industry, and is headquartered in Utah, USA.
What exchange does UTMD trade on?
Utah Medical Products trades on the Nasdaq under the ticker symbol UTMD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.